Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Diseases of the Thyroid

Free Subscription Articles published in J Nucl Med Retrieve available abstracts of 17 articles: HTML format

Single Articles

September 2025
1. CIUCIULKAITE I, Zuccotti GA, Jallo C, Hautzel H, et al
   Thyroid Hormone Withdrawal Yields Higher (131)I Absorbed Dose to Metastases Than rhTSH Stimulation in Differentiated Thyroid Cancer: Evidence from a Large (124)I PET/CT Dosimetry Cohort.
   J Nucl Med. 2025 Sep 25:jnumed.125.270391. doi: 10.2967/jnumed.125.270391.
   PubMed     Abstract available
   
   
   
2. WATABE T, Mukai K, Naka S, Sasaki H, et al
   First-in-Human Study of [(211)At]NaAt as Targeted alpha-Therapy in Patients with Radioiodine-Refractory Thyroid Cancer (Alpha-T1 Trial).
   J Nucl Med. 2025 Sep 25:jnumed.125.270810. doi: 10.2967/jnumed.125.270810.
   PubMed     Abstract available
   
   
   August 2025
3. UPRIMNY C, von Guggenberg E, Sviridenko A, Bayerschmidt S, et al
   Diagnostic Performance of the (68)Ga-Labeled Minigastrin Analog DOTA-MGS5 in Patients with Advanced Medullary Thyroid Cancer and Other Neuroendocrine Tumors.
   J Nucl Med. 2025 Aug 28:jnumed.125.269863. doi: 10.2967/jnumed.125.269863.
   PubMed     Abstract available
   
   
   June 2025
4. VON HINTEN J, Viering O, Bundschuh RA, Cagliyan F, et al
   Feasibility of Short-Term Redifferentiation in Patients with Radioactive Iodine-Refractory Metastatic Thyroid Cancer.
   J Nucl Med. 2025 Jun 5:jnumed.125.270055. doi: 10.2967/jnumed.125.270055.
   PubMed     Abstract available
   
   
   March 2025
5. WEIS H, Weindler J, Schmidt K, Hellmich M, et al
   Impact of Radioactive Iodine Treatment on Long-Term Relative Survival in Patients with Papillary and Follicular Thyroid Cancer: A SEER-Based Study Covering Histologic Subtypes and Recurrence Risk Categories.
   J Nucl Med. 2025 Mar 13:jnumed.124.269091. doi: 10.2967/jnumed.124.269091.
   PubMed     Abstract available
   
   
   January 2025
6. BARBRY F, Chevalier B, Beron A, Lion G, et al
   Redifferentiation of a RET-Fusion, Radioiodine-Refractory, Differentiated Thyroid Cancer with Selpercatinib: Flip-Flop Between [(18)F]FDG PET/CT and (131)I Posttreatment Scanning.
   J Nucl Med. 2025 Jan 16:jnumed.124.268539. doi: 10.2967/jnumed.124.268539.
   PubMed    
   
   
   
7. VON GUGGENBERG E, di Santo G, Uprimny C, Bayerschmidt S, et al
   Safety, Biodistribution, and Radiation Dosimetry of the (68)Ga-Labeled Minigastrin Analog DOTA-MGS5 in Patients with Advanced Medullary Thyroid Cancer and Other Neuroendocrine Tumors.
   J Nucl Med. 2025 Jan 16:jnumed.124.268877. doi: 10.2967/jnumed.124.268877.
   PubMed     Abstract available
   
   
   July 2024
8. AL-NAQEEB G, Munger E, Ramanathan AL, Makarewicz A, et al
   Paraplegic Patient with Metastatic Papillary Thyroid Cancer: A Multidisciplinary Approach to Radioactive Iodine Therapy Safety and Efficacy Strategy.
   J Nucl Med. 2024 Jul 11:jnumed.123.266955. doi: 10.2967/jnumed.123.266955.
   PubMed     Abstract available
   
   
   April 2024
9. GREENSPAN BS, Hofman MS, Buscombe J
   The Accomplishments and Legacy of Saul Hertz, MD.
   J Nucl Med. 2024;65:659-663.
   PubMed     Abstract available
   
   
   March 2024
10. KIM KJ, Choi J, Kim KJ, Song E, et al
    Cancer Risk in Graves Disease with Radioactive (131)I Treatment: A Nationwide Cohort Study.
    J Nucl Med. 2024 Mar 28:jnumed.123.266531. doi: 10.2967/jnumed.123.266531.
    PubMed     Abstract available
    
    
    
11. GREENSPAN BS, Hofman MS, Buscombe J
    Commentary on "Radioactive Iodine: A Living History".
    J Nucl Med. 2024;65:495.
    PubMed    
    
    
    December 2023
12. VENTURA D, Dittmann M, Buther F, Schafers M, et al
    Diagnostic Performance of [(18)F]TFB PET/CT Compared with Therapeutic Activity [(131)I]Iodine SPECT/CT and [(18)F]FDG PET/CT in Recurrent Differentiated Thyroid Carcinoma.
    J Nucl Med. 2023 Dec 21:jnumed.123.266513. doi: 10.2967/jnumed.123.266513.
    PubMed     Abstract available
    
    
    November 2023
13. GUNTHER T, Holzleitner N, Viering O, Beck R, et al
    Preclinical Evaluation of Minigastrin Analogs and Proof-of-Concept [(68)Ga]Ga-DOTA-CCK-66 PET/CT in 2 Patients with Medullary Thyroid Cancer.
    J Nucl Med. 2023 Nov 9:jnumed.123.266537. doi: 10.2967/jnumed.123.266537.
    PubMed     Abstract available
    
    
    
14. VIERING O, Gunther T, Holzleitner N, Dierks A, et al
    CCK(2) Receptor-Targeted PET/CT in Medullary Thyroid Cancer Using [(68)Ga]Ga-DOTA-CCK-66.
    J Nucl Med. 2023 Nov 2:jnumed.123.266380. doi: 10.2967/jnumed.123.266380.
    PubMed    
    
    
    October 2023
15. LASCHINSKY C, Theurer S, Herold T, Rawitzer J, et al
    Molecular Markers Are Associated with Onset of Radioiodine Refractoriness in Patients with Papillary Thyroid Carcinoma.
    J Nucl Med. 2023 Oct 26:jnumed.123.266044. doi: 10.2967/jnumed.123.266044.
    PubMed     Abstract available
    
    
    June 2023
16. ENKE JS, Bundschuh RA, Wienand G, Reitsam NG, et al
    Somatostatin Receptor Antagonists as a Theranostic Option in Iodine-Refractory Thyroid Carcinoma.
    J Nucl Med. 2023 Jun 15:jnumed.123.265639. doi: 10.2967/jnumed.123.265639.
    PubMed    
    
    
    April 2023
17. TAPROGGE J, Abreu C, Yusuf S, Ainsworth G, et al
    The Role of Pretherapy Quantitative Imaging and Dosimetry in Radioiodine Therapy for Advanced Thyroid Cancer.
    J Nucl Med. 2023 Apr 28:jnumed.122.264913. doi: 10.2967/jnumed.122.264913.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Diseases of the Thyroid is free of charge.